FLGR242

a purported albumin-binding follistatin construct whose sequence, identity, activity, animal record, human record, and claimed 19-day half-life could not be verified.

tier F · growth hormone · 0 peer-reviewed FLGR242 characterizations located

verdict

the file fails at identity before efficacy can be graded: the marketed name does not resolve to a characterized test article in the primary record.

if you're asking what FLGR242 is — the market describes it as a modified follistatin or myostatin-binding construct with albumin-binding behavior. no peer-reviewed paper, patent example, public sequence, or regulator record located in this review establishes that FLGR242 is that molecule.

if you're asking whether the generic GLYCLOK patent proves its identity — no. US20260008820 describes a broad glycopeptide albumin-binding platform. the accessible document does not identify FLGR242, a follistatin sequence, or an FLGR242 pharmacokinetic result. platform plausibility cannot authenticate a retail product.

if you're asking whether follistatin biology supports the claim — follistatin and myostatin biology are real, but that literature belongs to named, characterized molecules. it cannot be borrowed by an uncharacterized market name without sequence, structure, binding, and activity evidence.

if you're asking whether the half-life is 19 days — there is no FLGR242-specific concentration-time study supporting that figure. the number stays absent rather than being promoted from vendor copy.

No dosing table is created because no traceable FLGR242 administration study was located in any species.

why F-tier

F-tier follows directly from the identity rule. No peer-reviewed characterization, exact sequence, animal study, human trial, or compound-specific PK source was located. The generic GLYCLOK patent does not name or exemplify FLGR242, and the vendor half-life cannot substitute for a concentration-time study. The page cannot grade efficacy for a test article it cannot identify.

the core tension

The platform story is plausible enough to sound technical, while the product-specific evidence needed to connect that story to FLGR242 is absent. Without identity, every efficacy, half-life, and safety claim is downstream speculation.

what it is

A defensible molecular description requires at least a sequence or exact chemical structure, declared modifications, expression or synthesis method, and evidence that the resulting material has the intended fold and activity. FLGR242 has none of those in the located public primary record. The site therefore describes only what the market purports it to be and does not assert that a vial contains follistatin, an albumin binder, or any particular construct.

what it does

Unknown. A genuine follistatin-derived construct could in principle bind activin-family ligands including myostatin. That conditional mechanism says nothing about the identity, binding profile, potency, tissue distribution, or safety of FLGR242. Off-target activin-family binding is also biologically consequential and cannot be treated as a generic muscle-only pathway.

origin

The name appears in research-chemical commerce without a matching peer-reviewed characterization or registered clinical program located under FLGR242. A 2026 GLYCLOK patent supplies a broad albumin-binding platform concept, but its accessible text does not name or exemplify FLGR242.

why researchers are interested

The sales story combines two powerful ideas: myostatin blockade for muscle growth and albumin binding for long duration. Both ideas are scientifically legible. Neither proves that the marketed material has the asserted sequence, activity, exposure, or safety.

does it work

There is no usable FLGR242-specific evidence base. F-tier is an identity and evidence failure, not a judgment about what a hypothetical, correctly characterized follistatin construct might do.

claims vs the data

• FLGR242 is a long-acting follistatin construct — unverified — the description appears in marketing, while no sequence, structural characterization, or product-specific primary paper was located.
• FLGR242 binds albumin — unverified — a generic albumin-binding patent platform cannot establish binding by an unnamed commercial test article.
• FLGR242 has a 19-day half-life — unsupported — no FLGR242-specific concentration-time study supports the number.
• a high purity result establishes product identity — contradicted — purity is one property. it does not establish sequence, modification, fold, biological activity, sterility, or endotoxin burden.

key facts

• molecular formula: unknown; no verified FLGR242 sequence or structure
• molecular weight: unknown; no verified construct mass
• amino acids: unknown; no public sequence verified
• half-life: unknown; the marketed 19-day claim lacks an FLGR242-specific primary PK source
• type: purported albumin-binding follistatin or myostatin-pathway biologic; identity unverified
• CAS: none verified
• 0 peer-reviewed FLGR242 papers located
• 0 registered FLGR242 human trials located
• 0 traceable animal administration studies
• unknown sequence, molecular mass, and half-life

frequently asked questions

What is FLGR242?

It is a market name for a purported long-acting follistatin or myostatin-binding construct. Its exact sequence, modifications, formula, mass, and biological identity were not verified in the located primary record.

Is FLGR242 the same as follistatin 344?

That cannot be established. No public sequence or head-to-head identity record was located. It must not inherit follistatin 344 evidence by naming similarity.

Does FLGR242 have a 19-day half-life?

No primary FLGR242 pharmacokinetic source was located for that claim. The number appears in vendor marketing and is omitted from the site's PK data.

Does a certificate showing purity confirm FLGR242?

No. Purity by one analytical method does not establish amino-acid sequence, correct modification, folding, ligand binding, potency, sterility, endotoxin, aggregation, or vial content.

Is FLGR242 safe?

No safety conclusion is possible. Identity is unresolved, no animal or human safety study was located, and the purported pathway affects multiple TGF-beta-family ligands rather than a muscle-only switch.

related peptides

• follistatin 344 — a different named follistatin product with its own severe evidence and identity gaps
• igf-1 lr3 — another F-tier muscle-market compound, but with a defined molecular identity
• hgh — a clinically characterized GH-axis comparator; FLGR242 is not a GH agonist

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.